Ameriprise
HRTX icon

Ameriprise’s Heron Therapeutics HRTX Stock Holding History

Ameriprise’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-277,538
Closed -$286K – 3929
2023
Q3 		$286K Sell
277,538
-9,633
-3% -$13.7K ﹤0.01% 3598
2023
Q2 		$333K Sell
287,171
-65,603
-19% -$117K ﹤0.01% 3580
2023
Q1 		$533K Buy
352,774
+100,133
+40% +$251K ﹤0.01% 3411
2022
Q4 		$631K Buy
252,641
+3,435
+1% +$11.1K ﹤0.01% 3317
2022
Q3 		$1.05M Sell
249,206
-9,029
-3% -$35.3K ﹤0.01% 3090
2022
Q2 		$720K Buy
258,235
+36,677
+17% +$147K ﹤0.01% 3252
2022
Q1 		$1.27M Buy
221,558
+25,665
+13% +$188K ﹤0.01% 3108
2021
Q4 		$1.79M Buy
195,893
+28,314
+17% +$289K ﹤0.01% 2991
2021
Q3 		$1.79M Buy
167,579
+41,146
+33% +$501K ﹤0.01% 2908
2021
Q2 		$1.96M Buy
126,433
+42,411
+50% +$675K ﹤0.01% 2939
2021
Q1 		$1.36M Sell
84,022
-16,915
-17% -$302K ﹤0.01% 3008
2020
Q4 		$2.14M Sell
100,937
-4,914
-5% -$85.4K ﹤0.01% 2768
2020
Q3 		$1.57M Sell
105,851
-30,977
-23% -$483K ﹤0.01% 2783
2020
Q2 		$2.01M Sell
136,828
-43,635
-24% -$717K ﹤0.01% 2604
2020
Q1 		$2.12M Buy
180,463
+59,304
+49% +$1.11M ﹤0.01% 2443
2019
Q4 		$2.85M Buy
121,159
+26,471
+28% +$586K ﹤0.01% 2554
2019
Q3 		$1.75M Buy
94,688
+5,925
+7% +$109K ﹤0.01% 2763
2019
Q2 		$1.65M Sell
88,763
-10,443
-11% -$209K ﹤0.01% 2854
2019
Q1 		$2.42M Sell
99,206
-72,037
-42% -$1.89M ﹤0.01% 2649
2018
Q4 		$4.44M Buy
171,243
+89,951
+111% +$2.47M ﹤0.01% 2197
2018
Q3 		$2.57M Buy
81,292
+13,889
+21% +$517K ﹤0.01% 2715
2018
Q2 		$2.62M Buy
67,403
+16,337
+32% +$520K ﹤0.01% 2612
2018
Q1 		$1.41M Buy
+51,066
New +$1.16M ﹤0.01% 2828
2015
Q3 		– Sell
-114,472
Closed -$3.57M – 3894
2015
Q2 		$3.57M Buy
114,472
+37,870
+49% +$713K ﹤0.01% 2369
2015
Q1 		$1.11M Buy
+76,602
New +$863K ﹤0.01% 2888

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ameriprise's HRTX Position: Q4 2023 in Review

Ameriprise sold out of Heron Therapeutics (HRTX) in Q4 2023, closing a stake of 277,538 shares — an estimated $286K sold.

Ameriprise first reported a position in HRTX in Q1 2015 and held it in 25 quarters. The position peaked at $4.44M in Q4 2018. 151 funds tracked by Wall St. Rank hold HRTX as of Q4 2023.

  • Ameriprise reported no remaining Heron Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 277,538 Heron Therapeutics shares in Q4 2023, an estimated $286K.
  • Ameriprise first reported a position in Heron Therapeutics in Q1 2015 and held it in 25 quarters.
  • Ameriprise's Heron Therapeutics position peaked at $4.44M in Q4 2018.
  • 151 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.